Figure 7
Figure 7. Effect of a neutralizing antihuman TNFα mAb on Ang-II-induced MCP-1, RANTES, IL-8, and MCP-3 release from HUAECs, MIP-1α, and IL-8 release in human whole blood. HUAECs and human whole blood were stimulated with Ang-II (1 μM) or with 1 μM Ang-II plus anti-TNFα mAb (2 μg/mL). The release of MCP-1, RANTES, and IL-8 at 4 hours (A) and MCP-1 and MCP-3 at 24 hours (B; pM in the cell supernatant) as well as the release of MIP-1α (C) and IL-8 (D; pM in the plasma) in response to Ang-II was measured by ELISA and is expressed as mean (± SEM) of 4 to 6 experiments: *P < .05 or **P < .01 relative to values in the medium control group; + P < .05 relative to the 1 μM Ang-II group.

Effect of a neutralizing antihuman TNFα mAb on Ang-II-induced MCP-1, RANTES, IL-8, and MCP-3 release from HUAECs, MIP-1α, and IL-8 release in human whole blood. HUAECs and human whole blood were stimulated with Ang-II (1 μM) or with 1 μM Ang-II plus anti-TNFα mAb (2 μg/mL). The release of MCP-1, RANTES, and IL-8 at 4 hours (A) and MCP-1 and MCP-3 at 24 hours (B; pM in the cell supernatant) as well as the release of MIP-1α (C) and IL-8 (D; pM in the plasma) in response to Ang-II was measured by ELISA and is expressed as mean (± SEM) of 4 to 6 experiments: *P < .05 or **P < .01 relative to values in the medium control group; + P < .05 relative to the 1 μM Ang-II group.

Close Modal

or Create an Account

Close Modal
Close Modal